# Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection

> **NCT06968806** · PHASE3 · RECRUITING · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 360 (estimated)

## Conditions studied

- Aortic Dissection
- Inflammation

## Interventions

- **DRUG:** Ketorolac
- **DRUG:** 0.9 % saline

## Key facts

- **NCT ID:** NCT06968806
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-27
- **Primary completion:** 2027-09-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2025-11-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06968806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06968806, "Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06968806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*